Crescent Biopharma Inc recently disclosed that certain revenues recognized in its 2025 financial report actually originate from a $20 million upfront payment made by Kelun-Biotech under a licensing agreement between the two parties for the core asset Cr-001.
Show original
This financial arrangement highlights the commercial value of the Cr-001 project and the recognition from its partners. The confirmation of this funding strictly follows relevant accounting standards, reflecting the direct contribution of the authorized transaction to Crescent Biopharma's short-term financial performance.
0
0
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
PoolX: Earn new token airdrops
Lock your assets and earn 10%+ APR
Lock now!
You may also like
Federal Reserve Beige Book: Most districts expect slight and moderate economic growth
华尔街见闻•2026/03/04 19:10
Putin: Russia remains a reliable energy supplier for all partners
华尔街见闻•2026/03/04 18:53
Trending news
MoreFederal Reserve Beige Book: Most districts expect slight and moderate economic growth
At a major industry conference hosted by Morgan Stanley, the CEO of semiconductor giant Texas Instruments revealed that the company's acquisition plan for Silicon Labs is expected to be officially completed in the first half of 2027.
Crypto prices
More
Bitcoin
BTC
$73,751.99
+7.52%
Ethereum
ETH
$2,174.14
+9.40%
Tether USDt
USDT
$1
+0.03%
BNB
BNB
$662.23
+4.37%
XRP
XRP
$1.46
+6.62%
USDC
USDC
$1
+0.00%
Solana
SOL
$92.57
+8.58%
TRON
TRX
$0.2871
+2.22%
Dogecoin
DOGE
$0.1024
+14.19%
Cardano
ADA
$0.2819
+5.83%
How to buy BTC
Bitget lists BTC – Buy or sell BTC quickly on Bitget!
Trade now
Become a trader now?A welcome pack worth 6200 USDT for new users!
Sign up now